Abstract
The p53 tumor suppressor protein can function as an activator and a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 is poorly understood. To aid in clarifying this mechanism, we carried out studies designed to identify specific target genes that are down-regulated following p53 induction. Among the negative p53-response genes revealed by our screening protocols are those encoding stathmin (Op18), a tubulin-associated protein implicated in cell signaling pathways, and an FK506/rapamycin-binding protein, FKBP25. Stathmin and FKBP25 exhibit decreased expression in both human and murine immortalized and transformed cell lines following induction of wild-type p53 by several stimuli that result in DNA damage. Candidate p53-repressed genes such as these provide the necessary markers to delineate the mechanism and biological consequences of transcriptional repression mediated by p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barak Y, Juven T, Haffner R and Oren M. . 1993 EMBO J. 12: 461–468.
Belmont LD and Mitchison TJ. . 1996 Cell 84: 623–631.
Bièche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R and Curmi PA. . 1998 Br. J. Cancer 78: 701–709.
Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nanberg E, Sideras P and Gullberg M. . 1993 Leukemia 7: 569–579.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.
Gottlieb TM and Oren M. . 1996 Biochem. Biophys. Acta 1287: 77–102.
Gopalkrishnan RV, Lam EWF and Kedinger C. . 1998 J Biol. Chem. 273: 10972–10978.
Hanash SM, Strahler JR, Kuick R, Chu EHY and Nichols D. . 1988 J Biol. Chem. 263: 12813–12815.
Harvey DM and Levine AJ. . 1991 Genes Dev. 5: 2375–2385.
Haupt Y, Maya R, Kazaz A and Oren M. . 1997 Nature 387: 296–299.
Hirokawa N. . 1994 Curr. Opin. Cell Biol. 6: 74–81.
Hollstein M, Rice K, Greenblatt MS, Soussim T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC. . 1994 Nucl. Acids Res. 22: 3551–3555.
Jourdain L, Curmi P, Sobel A, Pantaloni D and Carlier M-F. . 1997 Biochemistry 36: 10817–10821.
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ. . 1992 Cell 13: 587–597.
Ko LJ and Prives C. . 1996 Genes Dev. 10: 1054–1072.
Kubbutat MHG, Jones SN and Vousden KH. . 1997 Nature 387: 299–303.
Landers JE, Cassel SL and George DL. . 1997 Cancer Res. 57: 3562–3568.
Leach SD, Scatena CD, Keefer CJ, Goodman HA, Young Song S, Yang L and Pietenpol JA. . 1998 Cancer Res. 58: 3231–3236.
Levine AJ. . 1997 Cell 88: 323–331.
Lu X and Lane DP. . 1993 Cell 75: 765–768.
Marklund U, Larsson N, Melander Gradin H, Brattsand G and Gullberg M. . 1996 EMBO J. 15: 5290–5298.
Miyashita T and Reed JC. . 1995 Cell 80: 293–299.
Momand J, Zambetti GP, Olson DC, George D and Levine AJ. . 1992 Cell 69: 1237–1245.
Murphy M, Hinman A and Levine AJ. . 1996 Genes Dev. 10: 2971–2980.
Okamoto K and Beach D. . 1994 EMBO J. 13: 4816–4822.
Olmsted JB. . 1991 Curr. Opin. Cell Biol. 3: 52–58.
Perry ME, Piette J, Zawadzki JA, Harvey D and Levine AJ. . 1993 Proc. Natl. Acad. Sci. USA 90: 11623–11627.
Roperch JP, Alvaro V, Prieur S, Tuynder M, Nemani M, Lethrosne F, Piouffre L, Gendron MC, Israeli D, Dausset J, Oren M, Amson R and Telerman A. . 1998 Nature Med. 4: 835–838.
Utrera R, Collavin L, Lazarevic D, Delia D and Schnieder C. . 1998 EMBO J. 17: 5015–5025.
Sobel A. . 1991 Trends Biochem. Sci. 16: 301–305.
Wang Q, Zambetti GP and Suttle DP. . 1997 Mol. Cell. Biol. 17: 389–397.
White E. . 1996 Genes Dev. 10: 1–15.
Wu X, Bayle JH, Olson D and Levine AJ. . 1993 Genes Dev. 7: 1126–1132.
Zhang CC, Yang J-M, White E, Murphy M, Levine AJ and Hait WN. . 1998 Oncogene 16: 1617–1624.
Acknowledgements
We would like to thank Suzanne Cassel for excellent assistance during the early phase of these studies, and Dr Michael Malim (University of Pennsylvania) for kindly providing the MT-2 and CEM-SS cell lines. This work was supported by grants NIH CA66741 (DL George) and NIH CA41086 AJ Levine, and by a generous grant from the WW Smith Charitable Trust (M Murphy).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ahn, J., Murphy, M., Kratowicz, S. et al. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18, 5954–5958 (1999). https://doi.org/10.1038/sj.onc.1202986
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202986
Keywords
This article is cited by
-
Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics
Nature Communications (2020)
-
Nam Dia long, a Vietnamese folk formula, induces apoptosis in MCF-7 cells through various mechanisms of action
BMC Complementary and Alternative Medicine (2017)
-
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells
Oncogene (2014)
-
Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer
Cancer Gene Therapy (2013)
-
Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med
Amino Acids (2012)